- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03263858
Vascular Implant Safety and Efficacy Study (BIOVITESSE)
July 9, 2020 updated by: Biotronik CRC Inc.
Assessment of the safety and clinical performance of a coronary stent system in de novo coronary artery lesions
Study Overview
Study Type
Interventional
Enrollment (Actual)
66
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Bern, Switzerland
- University Hospital Bern
-
Genève, Switzerland
- Hôpiteaux Universitaires Genève (HUG)
-
Lausanne, Switzerland
- Centre Hospitalier Universitaire Vaudois (CHUV)
-
Lugano, Switzerland
- Cardiocentro Ticino
-
Zürich, Switzerland
- University Hospital Zurich
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 85 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Subject is > 18 years and < 85 years old
- Written subject informed consent
- Subjects with stable or unstable angina pectoris or documented silent ischemia or hemodynamically stable NSTEMI patients
- Subject is eligible for percutaneous coronary intervention (PCI)
- Subject is acceptable candidate for coronary artery bypass surgery
- Subject is eligible for Dual Anti Platelet Therapy (DAPT)
- Subjects with a maximum of two single discrete de novo lesions in two separate native coronary arteries that can be treated with the study stent during the index procedure
- Reference vessel diameter of 3.0 mm to 3.8 mm by visual estimation.
- Target lesion length up to 22 mm by visual estimation.
- Target lesion with ≥ 50% and < 100% stenosis by visual estimation
Exclusion Criteria:
- Left main coronary artery disease
- Three-vessel coronary artery disease at the time of index procedure
- Angiographic evidence of thrombus in target vessel
- Chronic total occlusion
- Heavily calcified or extremely tortuous lesions that would prevent complete inflation of a pre-dilatation balloon
- Bifurcation lesion requiring side branch intervention, if side branches > 2mm in diameter are involved
- Ostial lesions (within 5 mm of vessel origin)
- In-stent restenosis
- Lesions with prior treatment with a drug coated balloon (DCB)
- Target lesion is located in or supplied by an arterial or venous bypass graft
- Target lesion requires treatment with. rotational atherectomy
- Proximal or distal to the target lesion located stenosis that might require future revascularization or impede run off detected during diagnostic angiography
- Previous treatment of target vessel within 9 months of index-procedure
- Patients with cardiogenic shock
- Documented left ventricular ejection fraction (LVEF) ≤ 30%
- Impaired renal function (serum creatinine > 2.5 mg/dl or 221 mmol/l, determined within 72 hours prior to intervention)
- Hemodynamically unstable NSTEMI or STEMI within 72 hours prior to index procedure
- Cerebrovascular event (within 3 months of index procedure)
- Subject is receiving oral or intravenous immuno-suppressive therapy (inhaled steroids are allowed) or has known life-limiting immunosuppressive or autoimmune disease (e.g. human immunodeficiency virus, systemic lupus erythematosus, but not diabetes mellitus)
- Known allergies to: Acetylsalicylic Acid (ASA), heparin, contrast medium, sirolimus, or similar drugs, exipients or the stent material
- Triple anticoagulation therapy
- Life expectancy less than 1 year
- Pregnant or breast-feeding females or females who intend to become pregnant during the time of the study
- Inability to understand or read the informed consent form
- Subject is currently participating in another study with an investigational device or an investigational drug and has not reached the primary endpoint yet
- In the investigators opinion subjects will not be able to comply with the follow-up requirements
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cohort 1 and 2
|
Implantation of coronary stent in de novo coronary artery lesions
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Strut coverage cohort 1
Time Frame: 1 month
|
Strut coverage will be assessed by OCT analysis
|
1 month
|
In stent late lumen loss cohort 2
Time Frame: 9 months
|
Late lumen loss with will be assessed by central QCA assessment
|
9 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
August 14, 2017
Primary Completion (Actual)
November 4, 2019
Study Completion (Actual)
January 28, 2020
Study Registration Dates
First Submitted
August 21, 2017
First Submitted That Met QC Criteria
August 23, 2017
First Posted (Actual)
August 28, 2017
Study Record Updates
Last Update Posted (Actual)
July 10, 2020
Last Update Submitted That Met QC Criteria
July 9, 2020
Last Verified
July 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- C1606
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Coronary Artery Disease
-
Elixir Medical CorporationIstituto Clinico HumanitasActive, not recruitingCoronary Artery Disease | Chronic Total Occlusion of Coronary Artery | Multi Vessel Coronary Artery Disease | Bifurcation of Coronary Artery | Long Lesions Coronary Artery DiseaseItaly
-
Fundación EPICActive, not recruitingCoronary Artery Disease | Left Main Coronary Artery Disease | Left Main Coronary Artery Stenosis | Restenosis, CoronarySpain
-
Peking Union Medical College HospitalNot yet recruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
Peking Union Medical College HospitalRecruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
IGLESIAS Juan FernandoUniversity of BernNot yet recruiting
-
National Institutes of Health Clinical Center (CC)National Heart, Lung, and Blood Institute (NHLBI)CompletedCoronary Arteriosclerosis | Coronary Artery Disease (CAD) | Obstructive Coronary Artery DiseaseUnited States
-
Barts & The London NHS TrustImperial College London; Brunel UniversityNot yet recruitingCORONARY ARTERY DISEASE
-
Fundación EPICRecruitingCoronary Artery Disease | Coronary Disease | Coronary Occlusion | Left Main Coronary Artery Disease | Coronary Artery StenosisSpain
-
Abbott Medical DevicesCompletedCoronary Artery Disease | Coronary Disease | Coronary Occlusion | Chronic Total Occlusion of Coronary Artery | Coronary Restenosis | Coronary Artery Stenosis | Coronary Artery RestenosisBelgium
-
China National Center for Cardiovascular DiseasesRecruitingLeft Main Coronary Artery DiseaseChina
Clinical Trials on Stent
-
Zhujiang HospitalNanfang Hospital of Southern Medical University; Guangdong Provincial People...UnknownTrials of Clinical Curative Effect, Follow-up Study and Hemodynamics of Treatment of IA Using StentsTreatment Outcome by Stent-assisted EmbolizationChina
-
Royal Sussex County HospitalTerumo CorporationCompletedCoronary DiseaseUnited Kingdom
-
Southeast University, ChinaUnknownEsophageal CancerChina
-
Baylor College of MedicineEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsTerminatedVaginal StrictureUnited States
-
Merit Medical Systems, Inc.CompletedVenous Stenosis | Venous OcclusionUnited Kingdom, Greece
-
UMC UtrechtUnknownAcute Coronary Syndrome | Stable Angina PectorisNetherlands, Luxembourg
-
Medinol Ltd.CompletedIschemic Heart DiseaseIsrael, Sweden, Belgium, Germany
-
Chang Gung Memorial HospitalNot yet recruitingVascular Response of Orsiro vs. Xience Drug-Eluting Stents for Treating Coronary Bifurcation LesionsCoronary Artery DiseaseTaiwan
-
Yonsei UniversityUnknownColorectal CancerKorea, Republic of
-
Biotronik, Inc.CompletedPeripheral Vascular Disease | Peripheral Artery DiseaseCanada, United States